These agonists provide essential requirements for initiating T cell‐mediated immunity, such as antigen uptake, processing and presentation by APCs, and the maturation and activation of T cells.[27] Chen et al. demonstrated that robust immunological responses driven by improved DC maturation could be achieved by combining PTT ablation with imiquimod, a potent TLR7 agonist.[28] Furthermore, anticytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) antibodies that inhibit the activities of Treg cells helped to inhibit tumor metastasis (Figure1A) successfully. This evidence concerns the gene TLR7 and neoplasm.